Accuray is highlighting that the company has 510(k) clearance pending from the U.S. Food and Drug Administration (FDA) for an online adaptive therapy option, Cenos, for its Radixact System.
The company has also received approval for its Tomo C radiation treatment delivery system by China’s National Medical Products Administration, it said.
Cenos and the Radixact System were unveiled in partnership with Limbus AI at the 2023 American Society for Radiation Oncology (ASTRO) annual meeting in San Diego, CA. Cenos is designed for medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table. With the addition of Cenos, Accuray customers will have the ability to perform online adaptation of their treatment plan to account for changes that may occur between treatment sessions.
Accuray also highlighted that the registration dossier for the CNNC-Accuray joint venture Tomo C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration.
The Tomo C platform features helical imaging and radiation delivery. With fully integrated treatment planning, centralized data management, and treatment delivery using patented beam-shaping technology, the system allows for greater control of the radiation dose, the company said.
Accuray also highlighted the system’s architecture and high-speed multileaf collimator for medical care teams to select from a range of delivery modalities. These include conventionally fractionated and ultra-hypofractionated treatments to optimize outcomes for standard radiation therapy indications. These include breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.